PMID- 24835866
OWN - NLM
STAT- MEDLINE
DCOM- 20150105
LR  - 20211203
IS  - 1536-3708 (Electronic)
IS  - 0148-7043 (Print)
IS  - 0148-7043 (Linking)
VI  - 72
IP  - 6
DP  - 2014
TI  - Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and 
      keloid scars.
PG  - 711-9
LID - 10.1097/SAP.0b013e31826956f6 [doi]
AB  - Excess scar formation after cutaneous injury can result in hypertrophic scar 
      (HTS) or keloid formation. Modern strategies to treat pathologic scarring 
      represent nontargeted approaches that produce suboptimal results. Mammalian 
      target of rapamycin (mTOR), a central mediator of inflammation, has been proposed 
      as a novel target to block fibroproliferation. To examine its mechanism of 
      action, we performed genomewide microarray on human fibroblasts (from normal 
      skin, HTS, and keloid scars) treated with the mTOR inhibitor, rapamycin. 
      Hypertrophic scar and keloid fibroblasts demonstrated overexpression of collagen 
      I and III that was effectively abrogated with rapamycin. Blockade of mTOR 
      specifically impaired fibroblast expression of the collagen biosynthesis genes 
      PLOD, PCOLCE, and P4HA, targets significantly overexpressed in HTS and keloid 
      scars. These data suggest that pathologic scarring can be abrogated via 
      modulation of mTOR pathways in procollagen and collagen processing.
FAU - Wong, Victor W
AU  - Wong VW
AD  - From the *Division of Plastic and Reconstructive Surgery, Department of Surgery, 
      Oregon Health and Science University, Portland, OR; and daggerDivision of Plastic and 
      Reconstructive Surgery, Department of Surgery, Stanford University, Stanford, CA.
FAU - You, Fanglei
AU  - You F
FAU - Januszyk, Michael
AU  - Januszyk M
FAU - Gurtner, Geoffrey C
AU  - Gurtner GC
FAU - Kuang, Anna A
AU  - Kuang AA
LA  - eng
GR  - T15 LM007033/LM/NLM NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Ann Plast Surg
JT  - Annals of plastic surgery
JID - 7805336
RN  - 0 (Immunosuppressive Agents)
RN  - 9007-34-5 (Collagen)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cicatrix, Hypertrophic/drug therapy/metabolism
MH  - Collagen/biosynthesis/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/physiology
MH  - Female
MH  - Fibroblasts/*drug effects
MH  - Humans
MH  - Immunosuppressive Agents/*pharmacology
MH  - Keloid/drug therapy/metabolism
MH  - Male
MH  - Middle Aged
MH  - Phosphorylation
MH  - Protein Array Analysis
MH  - Sirolimus/*pharmacology
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
PMC - PMC4886898
MID - NIHMS775726
EDAT- 2014/05/20 06:00
MHDA- 2015/01/06 06:00
PMCR- 2016/05/31
CRDT- 2014/05/20 06:00
PHST- 2014/05/20 06:00 [entrez]
PHST- 2014/05/20 06:00 [pubmed]
PHST- 2015/01/06 06:00 [medline]
PHST- 2016/05/31 00:00 [pmc-release]
AID - 00000637-201406000-00021 [pii]
AID - 10.1097/SAP.0b013e31826956f6 [doi]
PST - ppublish
SO  - Ann Plast Surg. 2014;72(6):711-9. doi: 10.1097/SAP.0b013e31826956f6.